tailieunhanh - Báo cáo hóa học: " Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab"

Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab | Campanella et al. Journal of Translational Medicine 2010 8 36 http content 8 1 36 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab Carla Campanella 1 Marcella Mottolese42 Anna Cianciulli3 Angela Torsello1 Roberta Merola3 Isabella Sperduti4 Elisa Melucci2 Salvatore Conti2 Maria Grazia Diodoro2 Massimo Zeuli1 Giancarlo Paoletti5 Francesco Cognetti1 and Carlo Garufi 1 Abstract Background Responsiveness to Cetuximab alone can be mediated by an increase of Epidermal Growth factor Receptor EGFR Gene Copy Number GCN . Aim of this study was to assess the role of EGFR-GCN in advanced colorectal cancer CRC patients receiving chemotherapy plus Cetuximab. Methods One hundred and one advanced CRC patients 43 untreated- and 58 pre-treated were retrospectively studied by fluorescence in situ hybridization FISH to assess EGFR-GCN and by immunohistochemistry IHC to determine EGFR expression. Sixty-one out of 101 patients were evaluated also for k-ras status by direct sequencing. Clinical end-points were response rate RR progression-free survival PFS and overall survival OS . Results Increased EGFR-GCN was found in 60 101 59 tumor samples. There was no correlation between intensity of EGFR-IHC and EGFR-GCN p . Patients receiving chemotherapy plus Cetuximab as first line treatment had a RR of 70 30 43 while it was 18 10 56 in the group with previous lines of therapy p . RR was observed in 29 60 48 of patients with increased EGFR-GCN and in 6 28 21 in those without p . At multivariate analyses number of chemotherapy lines and increased EGFR-GCN were predictive of response EGFR-IHC score increased EGFR-GCN and number of chemotherapy lines were significantly associated with a significant better PFS. Response to therapy was the only prognostic predictive factor for OS. In the 60 patients analyzed for .